Today's Trend
Nkarta, Inc. (NASDAQ: NKTX) shares fell today. Investors are reacting to mixed analyst activity: a bullish price-target increase offset by broad downward revisions to Nkarta’s multi-year earnings forecasts and a separate sell-side rating cut. Recent reported quarterly results also missed consensus, adding pressure.
- HC Wainwright’s price target (reported by American Banking News) was increased to $11.00 — a constructive signal about long‑term upside potential and program value that could support buying interest. Article
- HC Wainwright sharply cut EPS forecasts across multiple quarters and years in its March 26 research note: Q1 2026 to ($0.40) from ($0.34), Q2 to ($0.42) from ($0.36), Q3 to ($0.45) from ($0.38), Q4 to ($0.47) from ($0.41), FY2026 to ($1.74) from ($1.50), and material downgrades for FY2027–FY2030 (e.g., FY2027 now ($2.12) from ($1.84)). These lower model inputs signal slower cash runway/longer development timelines or higher costs, which is negative for the stock’s near‑term valuation. Article
- Wall Street Zen lowered its rating on Nkarta to "Sell" (reported by American Banking News), a direct negative for sentiment and potential catalyst for additional selling from fund managers or momentum traders. Article
Bottom line for investors: the upbeat price‑target move is outweighed today by fresh earnings cuts and a sell rating, which help explain the stock’s decline. Monitor upcoming operational updates, cash runway disclosures, and any clinical or partnership news that could materially change analyst views and sentiment.